Cytiva has decided to expand the Xcellerex X-platform portfolio to meet their growing needs with the addition of 500L and 2,000L bioreactors.

The X-platform is a reliable and flexible single-use system designed to increase operational efficiencies and production capacity while helping to lower costs, reduce risks, and bring life-changing therapeutics to the next clinical milestone faster.

Ludovic Brellier, President of Hardware Solutions, Cytiva, said, “Our customers need speed and flexibility to develop advanced therapeutics. The expansion of Cytiva’s Xcellerex X-platform portfolio and its additional features will help our customers scale their operations more efficiently. The design and functionality of the hardware, biocontainers and software will allow our customers to safely manufacture life-changing therapeutics faster.”

The X-platform bioreactor portfolio was designed to meet the process needs of early-stage clinical researchers all the way through to commercial manufacturing. Customers can easily scale from 50 L to 2,000 L and while also reducing the time spent optimizing.

Xcellerex single-use technologies were launched more than 20 years ago and have played a significant role in the development of protein-based therapeutics, such as monoclonal antibodies (mAbs). The technology is now playing a critical role in the development of advanced therapeutics, such as cell and gene therapies, mRNA vaccines, and antibody drug conjugates.